Compare OPRX & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPRX | SWKH |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Diversified Financial Services |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.6M | 205.9M |
| IPO Year | 2008 | N/A |
| Metric | OPRX | SWKH |
|---|---|---|
| Price | $7.40 | $16.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $19.67 | $18.00 |
| AVG Volume (30 Days) | ★ 420.0K | 7.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $92,127,000.00 | N/A |
| Revenue This Year | $19.77 | $52.93 |
| Revenue Next Year | $11.33 | N/A |
| P/E Ratio | $746.00 | ★ $9.18 |
| Revenue Growth | ★ 28.81 | N/A |
| 52 Week Low | $3.99 | $13.00 |
| 52 Week High | $22.25 | $18.66 |
| Indicator | OPRX | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 29.60 | 26.80 |
| Support Level | N/A | $16.15 |
| Resistance Level | $14.45 | $17.71 |
| Average True Range (ATR) | 0.70 | 0.26 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 6.49 | 12.90 |
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.